Reverse Transcriptase Enzyme Market Global Report 2026

The reverse transcriptase enzyme market size has grown rapidly in recent years. It will grow from $1.1 billion in 2025 to $1.21 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to expansion of molecular biology research activities, increasing utilization of RT-PCR technologies, growth in infectious disease testing programs, rising investment in life sciences research, and expanding adoption of gene expression studies.

The reverse transcriptase enzyme market size is expected to see rapid growth in the next few years. It will grow to $1.8 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth during the forecast period can be linked to rising demand for advanced RNA analytical tools, expansion of precision medicine programs, growing use of transcriptomic research applications, increased development of next-generation diagnostic assays, and higher investment levels in biotechnology innovation. Key trends anticipated in the forecast period include stronger demand for high-fidelity reverse transcriptase enzymes, increasing adoption of thermostable reverse transcriptase formulations, wider utilization of reverse transcriptase in RNA virus detection workflows, expansion of transcriptomics and gene expression analysis applications, and enhanced focus on optimizing enzyme performance in RT-PCR processes.

The rising prevalence of infectious diseases is expected to drive the growth of the reverse transcriptase enzyme market going forward. The incidence of infectious diseases refers to the number of newly reported infection cases within a defined population over a specific time period. The growing incidence of infectious diseases is largely attributed to increasing global population movement and urbanization, which facilitate the rapid spread of viral and bacterial infections across regions. Reverse transcriptase enzymes are widely used in infectious disease diagnostics to convert viral RNA into complementary DNA (cDNA) for detection and analysis in RT-PCR and other molecular diagnostic techniques. For instance, in March 2025, according to UK Health Security Agency, a UK-based agency responsible for all health security, tuberculosis (TB) cases rose by 11% in 2023 compared to 2022, while preliminary data for 2024 indicated an additional 13% increase, resulting in over 600 more reported TB diagnoses in 2024 than in 2023. Therefore, the rising incidence of infectious diseases is driving the growth of the reverse transcriptase enzyme market.

Leading companies operating in the reverse transcriptase enzyme market are focusing on developing advanced reverse transcriptases, such as engineered reverse transcriptase solutions to improve RNA analysis accuracy, enhance sensitivity, and support next-generation molecular diagnostics and sequencing applications. Engineered reverse transcriptase refers to a modified enzyme designed with enhanced thermal stability, fidelity, and processivity to improve complementary DNA synthesis and RNA detection performance. For example, in September 2025, Promega Corporation, a US-based biotechnology company, announced a strategic partnership with Watchmaker Genomics, a US-based biotechnology company, to launch a next-generation engineered reverse transcriptase enzyme platform for molecular diagnostics and genomics research applications. The collaboration aims to provide advanced enzyme technologies with improved performance for RNA sequencing, gene expression analysis, and clinical testing workflows.

In December 2023, Arbor Biotechnologies, a US-based biotechnology company, entered into a partnership with Ginkgo Bioworks Holdings Inc. to advance the discovery and development of precision gene-editing technologies. Through this collaboration, Arbor Biotechnologies and Ginkgo Bioworks Holdings Inc. aim to accelerate the optimization of novel gene-editing platforms, including reverse transcriptase-associated editing systems, by integrating Arbor’s proprietary genome editing platform with Ginkgo’s high-throughput mammalian cell engineering and automated Foundry capabilities, ultimately supporting the development of next-generation genetic medicines and therapeutic applications. Ginkgo Bioworks Holdings Inc. is a US-based biotechnology company specializing in cell programming and synthetic biology.

Major companies operating in the reverse transcriptase enzyme market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Merck KGaA, Illumina Inc., Agilent Technologies Inc., Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., TOYOBO CO. LTD., LGC Biosearch Technologies, Takara Bio Inc., Promega Corporation, New England Biolabs Inc., Vazyme Biotech Co. Ltd., Fapon Biotech Inc., Eurogentec S.A., Bioneer Corporation, Yeasen Biotechnology (Shanghai) Co. Ltd., ABclonal Technology Co. Ltd., Jena Bioscience GmbH, Watchmaker Genomics Inc., GeneCopoeia Inc., Aura Biotechnologies Pvt. Ltd.

North America was the dominant region in the reverse transcriptase enzyme market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in reverse transcriptase enzyme report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the reverse transcriptase enzyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The reverse transcriptase enzyme market consists of sales of reverse transcription kits, complementary deoxyribonucleic acid synthesis reagents, thermostable reverse transcriptase enzymes, and reverse transcription polymerase chain reaction enzyme systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The reverse transcriptase enzyme market research report is one of a series of new reports that provides reverse transcriptase enzyme market statistics, including reverse transcriptase enzyme industry global market size, regional shares, competitors with a reverse transcriptase enzyme market share, detailed reverse transcriptase enzyme market segments, market trends and opportunities, and any further data you may need to thrive in the reverse transcriptase enzyme industry. This reverse transcriptase enzyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.